[go: up one dir, main page]

CA2361437A1 - Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique - Google Patents

Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique Download PDF

Info

Publication number
CA2361437A1
CA2361437A1 CA002361437A CA2361437A CA2361437A1 CA 2361437 A1 CA2361437 A1 CA 2361437A1 CA 002361437 A CA002361437 A CA 002361437A CA 2361437 A CA2361437 A CA 2361437A CA 2361437 A1 CA2361437 A1 CA 2361437A1
Authority
CA
Canada
Prior art keywords
group
nicotine
pyridyl
azabicyclo
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361437A
Other languages
English (en)
Inventor
Pascal George
Pascale Robineau
Bernard Scatton
Dominique Caille
Samir Jegham
Branimir Zivkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361437A1 publication Critical patent/CA2361437A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouvelles compositions pharmaceutiques comprenant de la nicotine ou un ligand des récepteurs nicotiniques ainsi qu'un inhibiteur de la monoamine oxydase, destinées au sevrage tabagique.
CA002361437A 1999-02-02 2000-01-28 Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique Abandoned CA2361437A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR99/01144 1999-02-02
FR9901144A FR2788982B1 (fr) 1999-02-02 1999-02-02 Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
PCT/FR2000/000193 WO2000045846A1 (fr) 1999-02-02 2000-01-28 Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique

Publications (1)

Publication Number Publication Date
CA2361437A1 true CA2361437A1 (fr) 2000-08-10

Family

ID=9541474

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361437A Abandoned CA2361437A1 (fr) 1999-02-02 2000-01-28 Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique

Country Status (8)

Country Link
EP (1) EP1150715A1 (fr)
JP (1) JP2002536342A (fr)
AR (1) AR028983A1 (fr)
AU (1) AU2298800A (fr)
CA (1) CA2361437A1 (fr)
FR (1) FR2788982B1 (fr)
HU (1) HUP0201279A2 (fr)
WO (1) WO2000045846A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US7429664B2 (en) 2002-09-25 2008-09-30 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7488737B2 (en) 2004-04-22 2009-02-10 Memory Pharmaceutical Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7625924B2 (en) 2004-12-22 2009-12-01 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8263619B2 (en) 2004-03-25 2012-09-11 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HRP20050506A2 (en) * 1997-12-31 2006-03-31 Pfizer Products Inc. Aryl fused azapolycyclic compounds
JP2002531456A (ja) 1998-11-27 2002-09-24 ニューロサーチ、アクティーゼルスカブ ８−アザビシクロ〔３．２．１〕オクト−２−エン及び−オクタン誘導体
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
NZ524202A (en) * 2000-10-13 2004-08-27 Neurosearch As Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
RU2282619C9 (ru) * 2001-04-20 2006-12-20 Пфайзер Продактс Инк. Способы получения замещенных арилконденсированных азаполициклических соединений, промежуточные продукты и способы их получения
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
PT1441708E (pt) 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
US7417049B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
JP4511196B2 (ja) * 2002-04-18 2010-07-28 アストラゼネカ・アクチエボラーグ チエニル化合物
HK1080470B (zh) * 2002-04-18 2008-03-07 Astrazeneca Ab 杂环化合物
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2007100430A2 (fr) * 2006-01-27 2007-09-07 Yale University Analogues de cystisine et d'acétylcholine et procédés de traitement des troubles de l'humeur
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (fr) 2006-05-09 2009-02-11 AstraZeneca AB Formes de sel de (2s)-(4e)-n-méthyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
WO2009058120A1 (fr) * 2007-11-02 2009-05-07 Sri International Modulateurs des récepteurs nicotiniques de l'acétylcholine
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
CN102905527B (zh) 2010-01-11 2016-08-24 阿斯特来亚治疗有限责任公司 烟碱型乙酰胆碱受体调节剂
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
US20130165511A1 (en) 2010-09-01 2013-06-27 TONIX Pharmaceuticals Holding Corp Treatment for cocaine addiction
US10653639B2 (en) * 2016-05-16 2020-05-19 Cv Sciences, Inc. Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2446895A (en) * 1994-04-22 1995-11-16 Assistance Publique - Hopitaux De Paris Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
US5803081A (en) * 1996-06-28 1998-09-08 Regent Court Technologies Tobacco and related products

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994199B2 (en) 2002-08-30 2011-08-09 Memory Pharmaceuticals Corporation Heterocyclic compounds, methods for the preparation thereof, and uses thereof
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
US7700630B2 (en) 2002-08-30 2010-04-20 Memory Pharmaceuticals Corporation Heterocyclic compounds, methods for the preparation thereof, and uses thereof
US7943773B2 (en) 2002-09-25 2011-05-17 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US8252811B2 (en) 2002-09-25 2012-08-28 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7429664B2 (en) 2002-09-25 2008-09-30 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US8134003B2 (en) 2002-09-25 2012-03-13 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7964600B2 (en) 2003-12-22 2011-06-21 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US7790722B2 (en) 2003-12-22 2010-09-07 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US8158629B2 (en) 2003-12-22 2012-04-17 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US8263619B2 (en) 2004-03-25 2012-09-11 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US8486937B2 (en) 2004-03-25 2013-07-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof
US8691841B2 (en) 2004-03-25 2014-04-08 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof
US7902217B2 (en) 2004-04-22 2011-03-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7488737B2 (en) 2004-04-22 2009-02-10 Memory Pharmaceutical Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
US7625924B2 (en) 2004-12-22 2009-12-01 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8273891B2 (en) 2006-09-22 2012-09-25 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Also Published As

Publication number Publication date
FR2788982A1 (fr) 2000-08-04
JP2002536342A (ja) 2002-10-29
EP1150715A1 (fr) 2001-11-07
WO2000045846A1 (fr) 2000-08-10
AU2298800A (en) 2000-08-25
AR028983A1 (es) 2003-06-04
FR2788982B1 (fr) 2002-08-02
HUP0201279A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
CA2361437A1 (fr) Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique
CA2744736C (fr) Compositions comprenant des agonistes nicotiniques et leurs procedes d'utilisation
US20020019421A1 (en) Compositions and therapy for substance addiction
JP2005519851A (ja) 早漏の治療のためのホスホジエステラーゼインヒビターの投与
JP2003506485A (ja) 肥満治療を意図した薬剤の製造のためのモノアミンオキシダーゼ阻害剤の使用
EP1539149A2 (fr) Methodes de traitement de troubles associes aux recepteurs mglu (metabotropiques du glutamate), notamment la dependance et la depression
JP2008533142A (ja) α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
JP2655706B2 (ja) 抗パーキンソン病エルゴリン誘導体
Rueter et al. A‐85380: A Pharmacological Probe for the Preclinical and Clinical Investigation of the α4β2 Neuronal Nicotinic Acetylcholine Receptor
IL155666A (en) Insomnia treatment
JP4287596B2 (ja) ニコチン依存症の治療のためのデオキシペガニン含有医薬組成物
NO332525B1 (no) Farmasoytisk formulering omfattende melatonin
EP2945637B1 (fr) Utilisation d'agonistes du recepteur nicotinique de l' acetylcholine alpha 7
ES2231162T3 (es) 3-ciclopropilmetoxi-4-difluorometoxi-n-(33,5-dicloropirid-4 il)benzamida en el tratamiento de la esclerosis multiple.
Wildeboer et al. Stimulation of the α4β2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice
JPWO2005009444A1 (ja) 医薬組成物
MXPA01007812A (en) Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
US20220211679A1 (en) Alpha 7 nicotinic acetylcholine receptor agonists
CA1330536C (fr) Medicament pour le traitement d'un trouble cognitif
KR20010052319A (ko) 노르아드레날린 리업테이크 억제제, 바람직하게는레복세틴과 핀돌롤의 신규 약물 복합제
CA1330534C (fr) Medicament pour le traitement de la toxicomanie
Wall Effects of TI-299423 on neuronal nicotinic acetylcholine receptors
HUP0401013A2 (hu) Hatóanyag-kombináció nikotinfüggőség gyógyszeres kezelésére és ezt tartalmazó gyógyszerkészítmény
CA1330535C (fr) Medicament pour le traitement de la depression
JP2005534665A (ja) うつ病の治療のためのｐｄｅ−ｖ阻害物質及びｎｋ１拮抗薬の組合せ

Legal Events

Date Code Title Description
FZDE Discontinued